Dare Bioscience, Inc. (DARE): Gross Profit
$734.4K
Year ended 2025-12-31
$372.8K
Trailing 12 months to 2026-09-30
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $734.4K | n/a | 2026-03-26, From 2025-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $734.4K | n/a |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $223.8K | +0.4% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $248.7K | -32.3% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $803.0K | -57.4% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $619.0K | -15.6% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $632.9K | -40.0% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$2.08M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $940.0K | n/a |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $703.2K | +53.1% |
Compare DARE, SXTP, SXTC, LGVN side by side · Screen every company in Pharmaceutical Preparations ↗